$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
103
Report
Login to post
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Tonix Pharmaceuticals (TNXP) Stock Analysis
Company Profile: Tonix Pharmaceuticals is a pharmaceutical company focused on developing innovative therapies for psychiatric and pain conditions. They are primarily involved in the research and development of biologics and small molecules to address unmet medical needs.
Earnings Forecast: The earnings forecast for Tonix Pharmaceuticals is as follows:
2024FY: Forecast EPS of -14.13 USD, forecast gross income of 12.54 million USD, and forecasting EBIT of -79.29 million USD.
2025FY: Forecast EPS of -22.58 USD, forecast gross income of 15.62 million USD, and forecasting EBIT of -76.56 million USD.
2026FY: Forecast EPS of -0.81 USD, forecast gross income of 40.89 million USD, and forecasting EBIT of -63.31 million USD.
Analyst Recommendation: According to analysts, there are 2 buy recommendations for the stock.
Analyst Target Price: The mean, low, and high target price estimates provided by 3 analysts are 20.5 USD, 2.5 USD, and 48.0 USD, respectively.
Capital Flow Data (5 Day): The recent capital flow data for Tonix Pharmaceuticals shows the following:
12-09: 202.9 thousand units (inflow)
12-10: -114.36 thousand units (outflow)
12-11: 353.31 thousand units (inflow)
12-12: -123.52 thousand units (outflow)
12-13: 640.58 thousand units (inflow)
Profiteer Ratio: The profiteer ratio as of 2024-12-16 is 0.9568.
Resistance and Support Price: The resistance price as of 2024-12-16 is 0.538 USD, and the support price is 0.288 USD.
Average Cost: The average cost as of 2024-12-16 is 0.3731 USD.
Earnings Result: The earnings result for the most recent quarter (2024Q3) includes the following metrics:
EPS: -0.23
ROE: -97.76%
Gross profit margin: 44.90%
Quick ratio: 2.48
Current ratio: 3.33
Total asset turnover: 0.14
Inventory turnover: 0.70
Return on investment: -57.92%
Operating cash flow to current liabilities ratio: -4.95
Fixed asset turnover: 0.26
Accounts receivable turnover ratio: 3.07
Net assets per share: 0.48
Total liabilities to total assets ratio: 10.48%
Return on total assets: -12.13%
Net profit margin: Not available
Stock Price: As of 2024-12-17, the stock price for Tonix Pharmaceuticals is 0.53 USD.
Analysis Summary:
Tonix Pharmaceuticals is a pharmaceutical company focused on developing therapies for psychiatric and pain conditions.
The earnings forecast shows a negative trend, with expected losses in the coming years.
Analysts have provided buy recommendations for the stock, with a wide range of target price estimates.
Capital flow data indicates mixed investor sentiment in recent days.
The stock has resistance at 0.538 USD and support at 0.288 USD.
The average cost is 0.3731 USD.
The recent earnings result shows negative EPS and low profitability ratios.
The stock price as of 2024-12-17 is 0.53 USD.
Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks carries inherent risks, and stock prices can fluctuate. It is recommended to conduct further research and analysis or consult with a professional financial advisor before making investment decisions.
Great article, would you like to share it?